0
Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¼¶À¯Á¶Á÷¿° ȯÀÚ¿¡ ´ëÇÑ ±âÃÊ Á¶»ç¿¬±¸

Survey on Fibromyalgia Syndrome

·ù¸¶Æ¼½º°Ç°­ÇÐȸÁö 1997³â 4±Ç 1È£ p.74 ~ 86
KMID : 0604719970040010074
ÇÑ»ó¼÷ (  ) - °æÈñ´ëÇб³ º´¼³°£È£Àü¹®´ëÇÐ ±³¼ö

°­Çö¼÷ (  ) - °æÈñ´ëÇб³ °£È£Çаú ±³¼ö

Abstract

¿ä¾à ¹× °á·Ð
¼¶À¯Á¶Á÷¿°¿¡ ´ëÇÑ ±âÃÊÀڷḦ ¾ò°íÀÚ ¼­¿ï½Ã¿¡ ÀÖ´Â H ´ëÇкμӺ´¿ø ·ù¸¶Æ¼½º³»°ú¸¦ ¹æ
¹®ÇÑ È¯ÀÚ 10,609¸í ¼¶À¯Á¶Á÷ ¿°À¸·Î Áø´Ü ¹ÞÀº ȯÀÚ¸¦ ´ë»óÀ¸·Î 1996³â 10¿ù 9ÀÏ ºÎÅÍ 11
¿ù 20ÀÏ »çÀÌ¿¡ ¹æ¹®ÇÑ 344¸íÀÇ È¯ÀÚ Áß¿¡¼­ Àǹ«±â·ÏÁö¸¦ ÀÚ·á·Î º» Á¶»ç¸¦ ½ÃµµÇÏ¿´´Ù.
±×Áß ¾ÐÅëÁ¡ ¼ö¿Í À§Ä¡ ¹× Á¤È®ÇÑ Áø´ÜÀÌ ±âÀçµÇÁö ¾Ê¾Æ ¿¬±¸ÀÚ°¡ ÀǵµÇÑ Á¶»ç³»¿ëÀ» ÃæÁ·
½Ãų ¼ö ¾ø´Â 6°÷»ç·Ê¸¦ Á¦¿ÜÇÑ ÈÄ ºÐ¼®ÀÌ °¡´ÉÇÑ ´ë»óÀ¸·Î 280»ç·Ê¸¦ ºÐ¼®ÇÏ¿´À¸¸ç °á°ú´Â
´ÙÀ½°ú °°´Ù.
1. ¼¶À¯Á¶Á÷¿°À¸·Î Áø´Ü¹ÞÀº 280¸í Áß °ÅÀÇ ¸ðµÎ°¡ 279(99.6%)´Â ¿©ÀÚ¿´À¸¸ç ³â·ÉºÐÆ÷´Â
28-76¼¼¿´°í, 51-60¼¼ (41.4%)°¡ °¡Àå ¸¹¾ÒÀ¸¸ç Æò±Õ¿¬·ÉÀº 52.4¼¼¿´´Ù. ¶ÇÇÑ À̵éÀÇ °ÅÁÖÁö
¸¦ º¸¸é ¼­¿ï(42.5%)ÀÌ °¡Àå ¸¹¾ÒÀ¸³ª ´ë»óÀÚÀÇ °ÅÁÖÁö ºÐÆ÷´Â Àü±¹¿¡ °ÉÃÄÀÖ¾î ´ë»óÀÚ°¡
Ä¡·á¸¦ À§ÇÏ¿© ¸Õ °÷±îÁö ¹æ¹®ÇÏ°í ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù.
2. ¿Ü·¡ ¹æ¹® Ä¡·á±â°£ÀÌ 6°³¿ù ¹Ì¸¸ÀÌ 46.1%¸íÀ¸·Î °¡Àå ¸¹¾Ò°í, ±× ´ÙÀ½ÀÌ 3³â(22.1%),
2 ³â(12.5%) ¼øÀ̾úÀ¸¸ç Æò±Õ±â°£Àº 1³â 7°³¿ùÀ̾ú´Ù ÀÌ·¯ÇÑ °á°ú¸¦ °í·ÁÇÒ ¶§ ¾ÕÀ¸·Î ´õ¿í
¸¹Àº ȯÀÚ°¡ ¸¸¼ºÈ­µÊ¿¡ µû¶ó ȯÀÚÀÇ ¼ö´Â Áõ°¡µÇ°í ´©ÀûµÇ¸®¶ó º»´Ù.
3. ¼¶À¯Á¶Á÷¿°È¯ÀÚÀÇ µ¿¹Ý ÁúȯÀ» º¼ ¶§ ¼¶À¯Á¶Á÷ ¿°¸¸ ÀÖ´Â »ç·Ê´Â 39.3%·Î °¡Àå ¸¹¾Ò
°í, ±× ´ÙÀ½ÀÌ ¼¶À¯Á¶Á÷¿°°ú ÅðÇ༺°üÀý¿°À» °âÇÑ °æ¿ì 36.7%, ¼¶À¯Á¶Á÷¿°°ú ·ù¸¶Æ¼½º°üÀý
¿°À» °âÇÑ °æ¿ì ¼øÀ̾ú´Ù.
4. ´ë»óÀÚÁß ¾ÐÅëÁ¡(tender point)À» 10-12°³¸¦ °®°í ÀÖ´Â °æ¿ì 37.1%°¡ °¡Àå ¸¹¾Ò°í Æò±Õ
Àº 12.19°³¿´À¸¸ç ¾ÐÅëÁ¡ÀÌ À§Ä¡ÇÏ°í ÀÖ´Â °÷Àº ÁÖ·Î ÆȲÞÄ¡ÀÇ ¿ÜÃø»ó°ú(92.0%), °ß°©°ñ³»
Ãø(½Â¸ð±ÙÀÇ ±â½ÃºÎ, 84.8%), °ß°©±Ø À§ÂÊ(°ß°©»ó±Ù, 82.9%), ¹«¸­°üÀý ³»Ãø Áö¹æ(81.8%), 5¹ø
°¿Í 7¹ø° °æÃß»çÀÌ(C5-7, 73.4%), 2¹ø° ´Á°ñ(2¹ø° ´Á¿¬°ñ°üÀý ºÎÀ§,
72.0%)µî À̾ú´Ù. ¶ÇÇÑ °üÀý±â´ÉÀå¾Ö ¼ö°¡ ÀüÇô ¾ø´Â °æ¿ì(47.1%)°¡ °¡Àå ¸¹¾ÒÀ¸¸ç Æò±Õ
2.41°³¸¦ °®°í ÀÖ¾ú´Ù
5. ³â·É°ú ¾ÐÅëÁ¡ ¼ö¿ÍÀÇ °ü°è¿¡¼­ ³â·ÉÀÌ ³ôÀ»¼ö·Ï ¸¹Àº ¾ÐÅëÁ¡À» °®°í ÀÖ´Â Á£À¸·Î ³ª
Ÿ³µÀ¸³ª Åë°èÀûÀ¸·Î À¯ÀÇÇÑ Â÷ÀÌ´Â ¾ø¾ú°í(F=1. 47, P=0.20) ³â·Éº° °üÀý±â´ÉÀå¾Ö¼öµµ Â÷ÀÌ
°¡ ÀÖ¾úÀ¸³ª Åë°èÀûÀ¸·Î À¯ÀÇÇÑ Â÷ÀÌ´Â ¾ø¾ú´Ù(F=2.08, P=0.10). ¶ÇÇÑ ¾ÐÅëÁ¡¼ö¿¡ µû¸¥ °üÀý
±â´ÉÀå¾Ö ¼öµµ Â÷ÀÌ°¡ ÀÖ¾úÀ¸³ª Åë°èÀûÀ¸·Î À¯ÀÇÇÑ Â÷ÀÌ´Â ¾ø¾ú´Ù(F=1.48, P=0.21).
6. ¿¬·É°ú ¼¶À¯Á¶Á÷¿°ÀÇ µ¿¹Ý Áúȯ°ú´Â °ü·Ã¼ºÀÌ ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µÀ¸¸ç(¥ö
2=79.22, P=0.000) Áø´Ü¸í°ú °üÀý±â´ÉÀå¾Ö ¼ö¿ÍÀÇ °ü°è¿¡¼­ °üÀý±â´ÉÀå¾Ö°¡ ÇÏ
³ªµµ ¾ø´Â °æ¿ì 132¸íÁß ¼ø¼öÇÏ°Ô ¼¶À¯¼ºÁ¶Á÷ ¿°¸¸ °®°í ÀÖ´Â °æ¿ì°¡ 77¸í (58.3%)À¸·Î °¡
Àå ¸¹¾Ò°í, Áø´Ü¸í°ú °üÀý±â´É Àå¾Ö ¼ö(¥ö2=70.44, df=20, P=0.000)µµ °ü·Ã¼ºÀÌ
ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù.
ÀÌ»ó°ú °°Àº °á°ú¸¦ ÅëÇØ ¿ì¸® ³ª¶ó ÀüüÀÇ ¼¶À¯Á¶Á÷ ¿° ÀÌȯÀ²À» ¾Ë ¼ö´Â ¾øÀ¸³ª ¼¶À¯Á¶
Á÷ ¿° ȯÀÚÀÇ Àα¸ÇÐÀû Ư¼º, ¼¶À¯Á¶Á÷¿°ÀÇ Æ¯¼º°ú ¾ç»óÀ» ÆľÇÇÏ¹Ç·Î½á ¼¶À¯Á¶Á÷ ¿°È¯ÀÚÀÇ
Áõ»ó¿ÏÈ­¸¦ À§ÇÑ °£È£ÁßÀç¹ýÀ» ã´Âµ¥ µµ¿òÀÌ µÇ¸®¶ó º»´Ù.
#ÃÊ·Ï#
This investigation has been conducted based on the medical chart of 344 patients who
have been diagnosed of fibromyalgia syndrome during Oct. 9, 1996 through Nov. 20 at
the Rheumatism Hospital of H. University located in Seoul. 280 which have been
included in the analysis.
1. Only one patient was male in 280 patients, age distribution was from 28 to 76, in
which the average age was 52.4.
2. Percentage of treatment duration was 6 months in 46.1%, 3 years in 22.1% and 2
years in 12.5%. Considering these results, it can be predicted that the number of
patients might be increased and accumulated in the future.
3. Percentage of patients haying primary fibromyalgia syndrome was 39.3%, having
combination with osteoarthritis was 36.7% and the rest case have combination with
rheumatoid arthritis at the same time.
4. The percentage of cases having patients 10-12 tender points was 37 1%, while the
most of cases have pain at 12-19 tender points. The common locations of the tender
point were at lateral epicondyle of elbow in 92.0%, at midpoint of upper border
Trapezius in 84.8%, at upper part of scapula Supraspinatus in 82.9%, at medial fat pad
proximal to the joint line knee in 81.85%, at intertransverse of C5-7 Low
cervical in 73.4% and at 2nd distal costochondral junction 2nd rib in 72.0%. And most of
the patients had joint functional disability at all in 47.1% with aver age 2.41 joint
functional disability.
5. Age was not a variable influencing the number of tender points and the number of
Joint functional disability.

KeyWords

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
 
µîÀçÀú³Î Á¤º¸